Interim report January - June 2026

Q2

Strategic expansion, growth, and strengthened underlying profitability

April – June 2026

- On 1 June 2026, Genovis AB acquired 100% of the shares in KPL ApS, a Danish life science tools company with a proprietary portfolio of precision enzymes (proteases), including both commercialized products and products under development, for mass spectrometry-based protein analysis in academic research, diagnostics, and drug development.
- **Net sales** totaled SEK 34,316 (28,871) thousand, representing a growth of 19%, corresponding to 21% when adjusted for currency effects.
- **Operating profit before depreciation and amortization** (EBITDA) totaled SEK 6,844 (6,036) thousand which was affected by transaction costs of SEK 3,492 thousand related to the acquisition of KPL ApS. Adjusted for these costs, EBITDA amounted to SEK 10,336 thousand.
- **Earnings per share** totaled SEK 0.02 (0.08) which were affected by transaction costs related to the acquisition of KPL ApS. Adjusted for these costs, earnings per share amounted to SEK 0.07.
- **Cash flow from operating activities** was SEK 7,906 (-5,400) thousand.

January – June 2026

- **Net sales** totaled SEK 67,823 (61,163) thousand, representing growth of 11%, corresponding to 19% when adjusted for currency effects.
- **Operating profit before depreciation and amortization (**EBITDA**)** totaled SEK 16,354 (14,943) thousand and was affected by transaction costs of SEK 3,492 thousand related to the acquisition of KPL ApS. Adjusted for these costs, EBITDA amounted to SEK 19,846 thousand.
- **Earnings per share** totaled SEK 0.08 (0.13) and were affected by transaction costs related to the acquisition of KPL ApS. Adjusted for these costs, earnings per share amounted to SEK 0.14.
- **Cash flow from operating activities** was SEK 24,417 (5,251) thousand.

Sales by quarter 2023 – 2026



Comments from Fredrik Olsson, Chief Executive Officer

The second quarter was characterized by strategic expansion. We completed the acquisition of KPL, launched new products across several parts of the business and strengthened underlying profitability. The reported figures were affected by one-off costs related to the acquisition, but beneath the surface, they reflect a broader and more resilient business.

Net sales amounted to SEK 34,316 thousand (28,871), an increase of 19 percent compared with the corresponding period last year, or approximately 21 percent adjusted for currency effects.

Reported operating profit was affected by transaction-related one-off costs of approximately SEK 3.5 million associated with the acquisition of KPL. At the same time, underlying profitability strengthened significantly. Adjusted EBITDA amounted to SEK 10,336 thousand (6,036), corresponding to a margin of approximately 30 percent, while adjusted EBIT nearly doubled compared with the previous year. The acquisition will also result in increased depreciation and amortization of approximately SEK 0.7 million per quarter going forward. Excluding the one-off items, the underlying profitability trend was very strong and confirms the resilience of our business model during a period of strategic expansion.

Genovis is built on enzyme technologies used across three complementary areas:

- protein analysis and drug development
- Genomics based on our RNase inhibitor technology
- Proteomics with a growing offering following the acquisition of KPL

The established analysis business performed strongly during the quarter. Excluding the service business, product sales grew by approximately 20 percent, or approximately 22 percent adjusted for currency effects. Demand was healthy across several customer segments, with growth among both large pharmaceutical companies and biotechnology companies. The service business, however, was significantly weaker than in the corresponding quarter last year. As it is project-based, revenue varies between quarters, but we continue to see good opportunities to develop the business.

Genomics performed very strongly during the quarter and delivered its best quarter to date. Sales of SEQguard were the clearest growth driver and gained broad traction among leading academic institutions, largely through our partnership with Plasmidsaurus. At the same time, the business is broadening and becoming less dependent on individual large customers, making it more resilient. Genomics is on track to become a central part of our future growth.

Within the analysis business, our ADC technologies are currently used primarily for research and method development. We are also seeing growing interest in applying the same technologies to the development and manufacturing of new ADC therapeutics. Over time, this creates an opportunity to complement our product sales with licensing revenue and recurring revenue linked to commercial manufacturing. We are currently engaged in discussions with several customers that are evaluating our technologies for their clinical programs. This development remains at an early stage but represents a significant long-term growth opportunity.

During the quarter, we also continued to strengthen our platform. The acquisition of KPL on June 1 broadens our product portfolio and customer base within Proteomics and strengthens our position in an attractive market with favorable long-term growth prospects.

We also continue to develop our innovation platform. On June 26, we launched AlligBAITOR — a new product for antibody enrichment and native antigen release — and received the first orders before the end of the quarter, confirming early market interest.

Overall, the second quarter represented an important step in Genovis' development. We strengthened underlying profitability while continuing to broaden the business and create the conditions for sustained long-term growth.

A quarter of this magnitude places significant demands on the organization, and I would like to extend my sincere thanks to all Genovis employees for your commitment and your ability to deliver during a period of change. I would also like to warmly welcome our new colleagues from KPL. With a broader product portfolio and a more diversified business, I look forward to what we can achieve together during the second half of the year and to the opportunities ahead as we continue to create value for customers and shareholders.

The Genovis Group

Genovis will apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future.

Genovis develops and markets innovative enzyme technologies for research, development, and production within life science and biopharma.

The company's technologies are currently used in three complementary areas:

- Protein analysis and drug development
- Genomics
- Proteomics

Through continuous product development and strategic acquisitions, Genovis is progressively broadening its offering and creating multiple long-term growth opportunities.

The product portfolio today comprises a broad range of enzyme-based products and services for protein analysis, enzyme-based conjugation, and analytical services. The acquisition of SEQURNA AB in 2025 established a new business area within Genomics, based on a unique RNase inhibitor technology for RNA analysis and applications including mRNA manufacturing. During 2026, the Group was further expanded through the acquisition of KPL ApS, which established Genovis within Proteomics with a complementary product portfolio of enzymes for proteomics.

The parent company in Kävlinge is responsible for research and development, production, and sales and marketing in markets outside North America. The subsidiary Genovis Inc. is responsible for sales and marketing in North America, while sales in Asia are conducted mainly through local distributors. Genovis also has its own market presence through product specialists in Denmark, Germany, France, Spain, Italy, and China.

Genovis' business model is based on long-term, sustainable value creation through innovation, close customer relationships, and strategic broadening of the technology platform. The company's strategy is built on three main priorities:

- Continuing to launch new, unique products and services, thereby broadening the customer offering to support continued strong growth.
- Working purposefully to ensure that customers use Genovis products throughout the entire process, up to the release and approval of new biological drugs.
- Broadening the customer offering through inorganic growth initiatives such as in-licensing and the acquisition of technologies or companies.

An increasing number of customers are now using Genovis' technologies further along the development process, from early research to development, production, and quality control of biological drugs. This strengthens the company's long-term customer relationships and creates favorable conditions for continued growth.

Financial overview

The Group's financial performance in summary

	Apr-Jun		Jan-Jun		full year
(SEK 000s)	2026	2025	2026	2025	2025
Net Sales	34,316	28,871	67,823	61,163	128,946
Gross margin %[1]	88.3%	90.1%	88.0%	89.4%	89.3%
Operating profit before depreciation and amortization (EBITDA)	6,844	6,036	16,354	14,943	33,558
Operating margin before depreciation and amortization %[2]	19.9%	20.9%	24.1%	24.4%	26.0%
Operating profit (EBIT)	2,824	3,457	8,601	9,848	21,283
Operating margin %[3]	8.2%	12.0%	12.7%	16.1%	16.5%
Profit margin %[4]	3.8%	17.7%	8.2%	14.0%	18.2%
Earnings per share[5] (SEK)	0.02	0.08	0.08	0.13	0.36
Cash flow from operating activities	7,906	-5,400	24,417	5,251	32,022

[1] Gross margin is calculated by dividing the sum of net sales, change in inventory of finished goods and raw materials and consumables by net sales.
[2] Operating margin before depreciation and amortization is calculated by dividing operating profit before depreciation and amortization (EBITDA) by net sales.
[3] Operating margin is calculated by dividing operating profit (EBIT) by net sales.
[4] Profit margin is calculated by dividing profit for the period by net sales.
[5] Earnings per share are calculated by dividing profit by the weighted average number of shares during the year. There is no dilutive effect.

Revenue

Consolidated net sales for the second quarter totaled SEK 34,316 (28,871) thousand a growth in sales of 19%, and when adjusted for currency effects, 21%. The change in inventory, finished goods, amounted to SEK 1,200 (874) thousand. Capitalized work for own account amounted to SEK 628 (177) thousand. Other operating income totaled SEK 3,087 (704) thousand. Other operating income for the quarter mainly relates to foreign exchange gains (see also foreign exchange losses in other operating expenses under the expenses section below). These gains have primarily arisen from the translation of the company's assets and liabilities denominated in foreign currencies into SEK, with the largest impact related to USD.

Consolidated net sales for the first half of the year totaled SEK 67,823 (61,163) thousand, a growth of 11%, 19% when adjusted for currency effects. Net sales include approximately SEK 1 million in upfront license revenue related to the EndoS2 enzyme technology recognized in the first quarter, as previously communicated. The change in inventory, finished goods, amounted to SEK 592 (744) thousand. Capitalized work for own account amounted to SEK 887 (494) thousand. Other operating income amounted to SEK 6,238 (1,106) thousand. Other operating income mainly relates to foreign exchange gains (see also foreign exchange losses in other operating expenses under the expenses section below). These gains have primarily arisen from the translation of the company's assets and liabilities denominated in foreign currencies into SEK, with the largest impact related to USD.

Sales revenue, 12-month rolling (2024 – 2026)



Expenses

Consolidated expenses for the second quarter totaled SEK 36,407 (27,169) thousand. Expenses are allocated as follows: raw materials and consumables SEK 5,208 (3,721) thousand, personnel expense SEK 13,337 (11,802) thousand, other external expenses SEK 8,441 (7,191) thousand and other operating expenses SEK 5,401 (1,876) thousand. Personnel expenses increased compared with the previous year, primarily due to salary increases, new hires, additional employees acquired through the acquisition of Sequrna AB och KPL Aps. Other external expenses increased primarily due to the commencement of an ERP system implementation. Other operating expenses consist of transaction costs related to the acquisition of KPL amounting to SEK 3,492 thousand, as well as of exchange rate losses (see also foreign exchange gains in other operating income under the revenue section above). The exchange rate losses mainly arose from the revaluation of the company's assets and liabilities denominated in foreign currencies to SEK, with the largest impact related to the USD. Depreciation for the quarter amounted to SEK 4,020 (2,579) thousand. The increase in depreciation is attributable to amortization of a license recognized following the license agreement with Thermo Fisher in 2025, as well as amortization of SEK 950 thousand on identified assets, such as customer relationships and the development platform, in connection with the acquisitions of Sequrna AB in 2025 and KPL Aps in 2026, as well as depreciation of right-of-use assets for premises in Sequrna.

For the first half of the year, expenses totaled SEK 66,939 (53,659) thousand. Expenses are allocated as follows: raw materials and consumables SEK 8,701 (7,209) thousand, personnel costs SEK 26,548 (21,864) thousand, other external expenses SEK 15,832 (14,513) thousand, other operating expenses SEK 8,105 (4,978) thousand. The increase in personnel expenses is due to salary increases, new hires, additional employees following the acquisition of Sequrna AB and KPL Aps. Other external expenses increased primarily due to the commencement of an ERP system implementation. Other operating expenses consist of transaction costs related to the acquisition of KPL amounting to SEK 3,492 thousand, as well as of exchange rate losses. The losses mainly arose from the revaluation of the company's assets and liabilities denominated in foreign currencies into Swedish kronor, with the largest impact related to the USD. Depreciation and amortization for the first half of the year totaled SEK 7,753 (5,095) thousand. The increase in depreciation is due to depreciation of a license recognized following the license agreement with Thermo Fisher in 2025, depreciation of identified intangible assets, such as customer relationships and the development platform, arising from the acquisitions of Sequrna AB in 2025 and KPL Aps in 2026, as well as depreciation of right-of-use assets for premises in Sequrna.

Operating profit before depreciation and amortization (EBITDA)

For the second quarter, EBITDA totaled SEK 6,844 (6,036) thousand. Adjusted EBITDA, excluding items affecting comparability, amounted to SEK 10,336 thousand, adjusted for transaction costs of SEK -3,492 thousand related to the acquisition of KPL ApS. EBITDA was positively impacted by SEK 1,016 (-1,298) thousand due to exchange rate variances, primarily as a result of a stronger USD relative to SEK during the quarter.

For the first half of the year, EBITDA totaled SEK 16,354 (14,943) thousand. Adjusted EBITDA, excluding items affecting comparability, amounted to SEK 19,846 thousand, adjusted for transaction costs of SEK -3,492 thousand related to the acquisition of KPL ApS. EBITDA was positively impacted by SEK 1,464 (-4,001) thousand due to exchange rate variances, primarily as a result of a stronger USD relative to SEK.

Operating profit/loss (EBIT) per quarter



Operating profit (EBIT)

For the second quarter, EBIT totaled SEK 2,824 (3,457) thousand. Adjusted EBIT, excluding items affecting comparability, amounted to SEK 6,316 thousand, adjusted for transaction costs of SEK -3,492 thousand related to the acquisition of KPL ApS. Depreciation and amortization increased by SEK 1,441 thousand compared with the previous year, primarily due to the acquisition of intangible assets, which had a negative impact on EBIT. EBIT was positively impacted by SEK 1,016 (-1,298) thousand due to exchange rate variances, mainly because of a stronger USD relative to SEK during the quarter.

For the first half of the year, EBIT totaled SEK 8,601 (9,848) thousand. Adjusted EBIT, excluding items affecting comparability, amounted to SEK 12,093 thousand, adjusted for transaction costs of SEK -3,492 thousand related to the acquisition of KPL ApS. Depreciation and amortization increased by SEK 2,658 thousand compared with the previous year, primarily due to the acquisition of intangible assets, which had a negative impact on EBIT. EBIT was positively impacted by SEK 1,464 (-4,001) thousand due to exchange rate variances, mainly because of a stronger USD relative to SEK.

Taxes

The Group has a deferred tax asset of SEK 10,305 (8,904) thousand and relates to deferred tax on intra-group profit on inventories and right-of-use assets.

Deferred tax liability for the Group totals SEK 11,282 (0) thousand. The liability related to deferred tax on surplus values from the acquisition of Sequrna AB and KPL ApS.

Profit and comprehensive income for the period

Profit after tax for the second quarter was SEK 1,313 (5,117) thousand. Earnings per share for the second quarter, based on a weighted average of the number of outstanding shares, totaled SEK 0.02 (0.08) SEK. Adjusted earnings per share, excluding items affecting comparability, amounted to SEK 0.07, adjusted for transaction costs related to the acquisition of KPL ApS.

Comprehensive income for the second quarter totaled SEK 2,806 (6,231) thousand.

Profit after tax for the first half of the year totaled SEK 5,570 (8,573) thousand. Earnings per share, based on a weighted average of the number of outstanding shares, totaled SEK 0.08 (0.13). Adjusted earnings per share, excluding items affecting comparability, amounted to SEK 0.14, adjusted for transaction costs related to the acquisition of KPL ApS.

Comprehensive income for the first half of the year was SEK 8,645 (10,843) thousand.

Acquisition of KPL ApS

Genovis AB acquired 100% of the shares in KPL Aps on July 1, 2025, a Danish life science tools company with a proprietary portfolio of precision enzymes (proteases). The purchase price for the acquisition amounted to SEK 49,666 thousand, of which SEK 16,020 thousand was paid in cash, SEK 28,051 thousand was settled through newly issued shares to KPL’s founders, and the remaining portion is a contingent consideration. The contingent consideration is linked to the future commercial performance of KPL's products during the period from 1 June 2026 to 31 March 2029 (the "Earn-out Period"). The contingent consideration is conditional upon KPL's products achieving cumulative sales of SEK 24.4 million during the Earn-out Period and, accordingly, cannot be determined at the acquisition date. Subject to the condition being met, the contingent consideration will be paid in early 2030. At the acquisition date, the contingent consideration was measured at SEK 5,595 thousand. Transaction costs of SEK 3,492 thousand were recognized in the income statement as other operating expenses. The acquisition of KPL comprised net assets with a carrying amount of SEK 1,118 thousand and identified surplus values related to the development platform, including deferred tax, of SEK 21,455 thousand. Goodwill amounted to SEK 27,093 thousand and mainly represents future economic benefits in the form of expected synergies in sales and marketing functions, distribution channels, and geographical presence, as well as the collective expertise of the personnel in the acquired company.

KPL ApS reported net sales of DKK 969 thousand and profit for the year of DKK 14 thousand for the 2025/2026 financial year.

Acquisition Analysis

Acquired Net Assets (SEK 000s)	
Development platform	27,022
Inventories, trade receivables and other receivables	820
Cash and cash equivalents	460
Trade payables and other liabilities	-162
Deferred tax liability	-5,567
Total acquired net assets	**22,573**
Goodwill	27,093
Total purchase consideration	**49,666**
Allocation purchase consideration:	
Cash	16,020
Share issue in kind (newly issued shares to founders of KPL)	28,051
Contingent consideration	5,595

The acquisition analysis is subject to final adjustments no later than one year from the acquisition date.

Cash Flow Effect (SEK 000s)	
Transaction costs related to acquisition	-3,492
Operating activities	**-3,492**
Total purchase consideration	-49,666
Cash and cash equivalents in the acquired company	460
Investing activities	**-49,206**
Unpaid purchase consideration (contingent consideration)	5,595
Share issue in kind in connection with acquisition, net	27,833
Financing activites	**33,428**
Total cash flow effect, Group	**-19,270**

Investments

The Group's net capital expenditure for the second quarter totaled SEK 52,235 (9,378) thousand of which SEK 49,206 thousand is attributable to the purchase consideration for the acquisition of KPL ApS. SEK 1,624 (163) thousand is attributable to property, plant, and equipment. SEK 1,405 (9,215) thousand is attributable to investments in intangible assets, of which SEK 628 (177) thousand relates to capitalized work for own account for new product development and the remainder refers to investments in patents and licenses.

For the first half of the year, net capital expenditure totaled SEK 53,188 (9,898) thousand, of which SEK 49,206 thousand is attributable to the purchase consideration for the acquisition of KPL Aps. SEK 1,820 (163) thousand is attributable to property, plant, and equipment, primarily laboratory equipment, and SEK 2,162 (9,735) thousand relates to investments in intangible assets, of which SEK 887 (494) thousand relates to capitalized work for own account for new product development.

Cash flow and financial position

The total shareholders' equity for the Group was SEK 308,002 (238,815) thousand after taking the profit for the period into account. Equity per share based on the weighted average of the number of outstanding shares (basic and diluted) at the end of the period was SEK 4.65 (3.65) kr. The Group's equity ratio at the end of the period was 72 (71) %.

Consolidated cash flow for the second quarter totaled SEK -13,743 (-6,421) thousand. Adjusted cash flow, excluding the acquisition of KPL ApS and the related share issue, amounted to SEK 5,527 thousand. Cash flow from financing activities, including the share issue totaled SEK 30,586 (8,357) thousand.

For the first half of the year, consolidated cash flow was SEK -6,001 (-453) thousand. Adjusted cash flow, excluding the acquisition of KPL ApS and the related share issue, amounted to SEK 13,269 thousand. Cash flow from financing activities, including the share issue totaled SEK 22,770 (4,194) thousand.

Consolidated cash and cash equivalents at the end of the period amounted to SEK 157,191 (168,989) thousand. Taking expected revenue into account, the Board believes that the existing working capital is sufficient to run the Company over the next twelve months.

Only the Group has interest-bearing liabilities; they relate in their entirety to the present value of estimated future lease payments, which also include rent for premises.

Noncurrent lease liabilities maturing between 1-15 years totaled SEK 63,656 (71,512) thousand at the end of the period. Current lease liabilities maturing within 1 year totaled SEK 8,312 (2,939) thousand at the end of the period.

Employees

On June 30, 2026, the Group employed 42 (34) people. The Parent Company in Kävlinge employs 33 (30) people, in the subsidiary Sequrna AB, 3 (0) people are employed, in the subsidiary KPL ApS, 2 (0) people are employed and 4 (4) people work for the subsidiary Genovis Inc. in the US.

Share capital and the share

The share capital at the end of the quarter was SEK 16,864,595 and the total number of shares was 67,458,379 with a par value of SEK 0.25. As part of the acquisition of KPL ApS, a new share issue comprising 1,395,587 shares at a subscription price of SEK 20.10 per share was completed on June 1. The share issue increased the share capital by SEK 348,897 and increased equity by a net amount of SEK 27,833,364 after deduction of issue costs amounting to SEK 217,935.

Genovis shares are traded on Nasdaq Fourth North Growth Market under the ticker symbol GENO. Fourth North is Nasdaq’s European emerging market intended for growth companies.

Certified adviser

The Company’s Certified Adviser is DNB Carnegie Investment Bank AB

Parent Company

Net sales and operating income in the Parent Company are attributable to the primary and only business area: sales of products and/or research-based innovations.

Revenue

Revenue for the second quarter, including changes in inventories of finished goods and capitalized work for own account, totaled SEK 36,403 (29,949) thousand of which SEK 31,759 (29,084) thousand attributable to sales, SEK 1,224 (-15) thousand relating to a change in inventory of finished goods, SEK 477 (176) thousand arising from capitalized work for own account and SEK 3,007 (704) thousand in other operating income. For the first half of the year, revenue totaled SEK 67,218 (57,908) thousand, including SEK 59,207 (55,976) thousand attributable to sales, 1,336 (361) thousand relating to change in inventory, finished goods, SEK 666 (494) arising from capitalized work for own account and SEK 6,072 (1,077) thousand attributable to other revenue. Other revenue mainly relates to foreign exchange gains.

Expenses

The Parent Company's expenses for the second quarter totaled SEK 26,675 (21,934) thousand. For the first half of the year, expenses totaled SEK 50,891 (43,208) thousand.

Performance

The profit for the second quarter was SEK 8,170 (8,538) thousand while profit for the first half of the year was SEK 13,844 (14,519) thousand.

Investments

Net capital expenditure for the second quarter totaled SEK 55,995 (9,378) thousand of which SEK 53,158 thousand is attributable to the purchase consideration for the acquisition of KPL ApS. SEK 1,654 (163) thousand is attributable to property, plant, and equipment. SEK 1,183 (9,215) thousand is attributable to investments in intangible assets of which SEK 477 (176) thousand relates to capitalized work for own account for new product development and the remainder refers to investments in patents and licenses. For the first half of the year, net capital expenditure totaled SEK 56,752 (9,898) thousand, of which SEK 53,158 thousand is attributable to the purchase consideration for the acquisition of KPL Aps. SEK 1,654 (163) thousand attributable to property, plant, and equipment. SEK 1,940 (9,735) thousand is attributable to investments in intangible assets of which SEK 666 (494) thousand relates to capitalized work for own account for new product development and the remainder refers to investments in patents and licenses.

Subsidiary Genovis Inc.

The subsidiary Genovis Inc. handles all sales and distribution of SmartEnzymes™ in the North American market.

Subsidiary Sequrna AB

The subsidiary Sequrna AB develops and markets next-generation RNase inhibitors, making RNA sequencing workflows more accessible, affordable and sustainable. Genovis owns 100% of Sequrna AB as of July 1, 2025. In July 2025.

Subsidiary KPL ApS

The subsidiary KPL ApS is a life science tools company that develops and markets sequencing-grade recombinant proteases for bottom-up proteomics workflows — Lys-C, Arg-C Zero™, Trypsin RMS, and Trypsin/Lys premium mix. The company's products are used in mass spectrometry-based protein analysis within biopharmaceutical research and development, quality control, and academic research. Genovis has owned 100% of KPL ApS since June 1, 2026.

Other information

Events after the end of the period
No other significant events were reported after the end of the period.

Related party transactions
Genovis' board member and principal owner Mikael Lönn, who holds a 13.62% stake in Genovis, owns 15.27% of the shares in Redeye AB, for which Mikael Lönn is also a board member. Genovis purchased services from Redeye AB for a total of SEK 5 thousand during the first half of the year.

Outlook
Although the Life Science field is relatively independent of business cycles, periods of uncertainty can influence our customers' appetite to invest in new technology. With most development projects proceeding according to plan, Genovis is positioned to make additional advances with respect to both new products and sales in 2026. Even if external geopolitical factors and macroeconomic turmoil continue to represent an element of uncertainty, our current assessment is that our business opportunities and operational capacity are good.

Risk Factors
Genovis' general view of the financial risks that could affect operations has not changed since the description published in the most recent annual report. Genovis' business risks include the risk that anticipated revenue might not materialize since the Company is active in a market in which competing companies have substantially larger financial resources at their disposal. For a detailed overview of the Company's financial risks, please refer to pages 55-56 in Genovis' 2025 Annual Report.

Auditor's review
This report has not been reviewed by the Company's auditor.

Financial calendar

Interim report January 1 – September 30, 2026,	November 10, 2026
Year-End Report January 1 – December 31, 2026,	February 11, 2027
Interim report January 1 – March 31, 2027,	April 27, 2027

Reports may be downloaded at the Genovis website:
https://investor.genovis.com/en/financial-reports/ or requested from the company by phone or letter: Genovis AB, Box 4, 244 21 Kävlinge, Sweden. Tel.: 046-10 12 30

Forward-looking information
This report contains forward-looking information based on the current expectations of Group management at Genovis. Although the management believes that the expectations reflected in such forward-looking information are reasonable, no assurance can be given that such expectations will prove correct. Consequently, actual future results may vary materially from those implied in the forward-looking statements due to such changes in economic, market and competitive conditions, changes in the regulatory environment and other government actions, fluctuations in exchange rates and other factors.

Accounting policies

This interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting and the relevant provisions of the Swedish Annual Accounts Act. The report for the Parent Company has been prepared in accordance with chapter 9 of the Swedish Annual Accounts Act, Interim Reports. The accounting policies applied for the Group and the Parent Company are consistent with the accounting policies used in the preparation of the most recent annual report.

Financial information - Group

Statement of comprehensive income

	Apr-Jun		Jan-Jun		full year
(SEK 000s)	2026	2025	2026	2025	2025
Net sales	34,316	28,871	67,823	61,163	128,946
Change in inventory, finished goods	1,200	874	592	744	-120
Work performed by the entity and capitalised	628	177	887	494	705
Other operating income	3,087	704	6,238	1,106	3,294
	39,231	**30,626**	**75,540**	**63,507**	**132,825**
Raw materials and consumables	-5,208	-3,721	-8,701	-7,209	-13,679
Personnel expense	-13,337	-11,802	-26,548	-21,864	-47,079
Other external expenses	-8,441	-7,191	-15,832	-14,513	-29,007
Other operating expenses	-5,401	-1,876	-8,105	-4,978	-9,502
Operating profit before depreciation and amortization (EBITDA)	**6,844**	**6,036**	**16,354**	**14,943**	**33,558**
Depreciation, amortization and impairment of plant, property, and equipment and intangible assets	-4,020	-2,579	-7,753	-5,095	-12,275
Operating profit (EBIT)	**2,824**	**3,457**	**8,601**	**9,848**	**21,283**
Net financial items	-273	-172	-574	-286	-1,013
The share of profit or loss after tax from associates accounted for using the equity method	0	454	0	245	6,538
Profit before tax	**2,551**	**3,739**	**8,027**	**9,807**	**26,808**
Income tax	-1,238	1,378	-2,457	-1,234	-3,310
Profit for the period	**1,313**	**5,117**	**5,570**	**8,573**	**23,498**
Items that may be reclassified subsequently to profit or loss					
Translation of foreign subsidiary	1,493	1,114	3,075	2,270	4,206
Comprehensive income for the period*	**2,806**	**6,231**	**8,645**	**10,843**	**27,704**

** The entire profit is attributable to Parent Company shareholders*

	Apr-Jun		Jan-Jun		full year
	2026	2025	2026	2025	2025
Earnings per share (SEK)*	0.02	0.08	0.08	0.13	0.36
Comprehensive income per share (SEK)*	0.04	0.10	0.13	0.17	0.42
Number of shares					
Weighted average for the period	66,522,876	65,465,714	66,294,105	65,465,714	65,781,830
Number of shares at start of period	66,062,792	65,465,714	66,062,792	65,465,714	65,465,714
Proceeds from new share issue	1,395,587	0	1,395,587	0	597,078
Number of shares at end of period	67,458,379	65,465,714	67,458,379	65,465,714	66,062,792
Share price at end of period, SEK	19.70	26.50	19.70	26.50	21.25

** Based on weighted average of the number of outstanding shares (basic and diluted)*

Condensed Balance Sheet

(SEK 000s)	Jun. 30 2026	Jun. 30 2025	Dec. 31 2025
Assets			
Non Current assets			
Intangible assets	132,683	17,228	79,304
Property, plant and equipment	80,912	85,461	83,931
Financial assets	134	81	129
Deferred tax assets	10,305	8,904	7,948
Investments in associates accounted for using the equity method	0	11,467	0
Current assets			
Current assets	46,615	41,949	43,430
Cash and cash equivalents	157,191	168,989	163,192
Total assets	**427,840**	**334,079**	**377,934**
Equity and liabilities			
Equity	308,002	238,815	271,524
Deferred tax	11,282	0	6,061
Non Current liabilities	73,146	78,645	72,278
Current liabilities	35,410	16,619	28,071
Total equity and liabilities	**427,840**	**334,079**	**377,934**

Statement of Changes in Equity

(SEK 000s)	Jun. 30 2026	Jun. 30 2025	Dec. 31 2025
Opening balance	271,524	227,972	227,972
Profit for the period	5,570	8,573	23,498
Other comprehensive income for the period	3,075	2,270	4,206
Total comprehensive income for the period	**8,645**	**10,843**	**27,704**
Transactions with owners of the group			
Proceeds from new share issue, net	27,833	0	15,848
Sum transactions with owners of the group	**27,833**	**0**	**15,848**
Closing balance	**308,002**	**238,815**	**271,524**
Attributable to shareholders in Genovis AB	308,002	238,815	271,524

Key financial indicators	Jun. 30 2026	Jun. 30 2025	Dec. 31 2025
Equity/assets ratio (%)	72	71	72
Equity per share at end of period* (SEK)	4.65	3.65	4.13

** Based on weighted average of the number of outstanding shares (basic and diluted)*

Condensed Statement of Cash Flows

	Apr-Jun		Jan-Jun		full year
(SEK 000s)	2026	2025	2026	2025	2025
Operating profit for the period	**2,824**	**3,457**	**8,601**	**9,848**	**21,283**
Adjustment for items not affecting cash flow	4,020	2,580	7,753	5,095	12,275
Changes in working capital	1,335	-11,265	8,637	-9,406	-523
Net financial items	-273	-172	-574	-286	-1,013
Cash flow from operating activities	**7,906**	**-5,400**	**24,417**	**5,251**	**32,022**
Investing activities	-52,235	-9,378	-53,188	-9,898	-53,497
Cash flow after investing activities	**-44,329**	**-14,778**	**-28,771**	**-4,647**	**-21,475**
Financing activities	30,586	8,357	22,770	4,194	15,225
Cash flow for the period	**-13,743**	**-6,421**	**-6,001**	**-453**	**-6,250**
Cash and cash equivalents at start of period	170,934	175,410	163,192	169,442	169,442
Cash and cash equivalents at end of period	**157,191**	**168,989**	**157,191**	**168,989**	**163,192**

Financial information – Parent Company

Condensed Income Statement

	Apr-Jun		Jan-Jun		full year
(SEK 000s)	2026	2025	2026	2025	2025
Operating income incl. change in inventory of finished goods and capitalised work performed for own account	36,466	29,949	67,281	57,908	111,877
Operating expenses	-26,675	-21,934	-50,891	-43,208	-87,013
Operating profit	**9,791**	**8,015**	**16,390**	**14,700**	**24,864**
Net financial items	551	780	1,111	1,633	2,667
Profit after financial items	**10,342**	**8,795**	**17,501**	**16,333**	**27,531**
Group contribution paid	0	0	0	0	-16,796
Appropriations	0	0	0	0	-515
Profit before tax	**10,342**	**8,795**	**17,501**	**16,333**	**10,220**
Income tax	-2,172	-257	-3,657	-1,814	-2,133
Profit for the period	**8,170**	**8,538**	**13,844**	**14,519**	**8,087**

Condensed Balance Sheet

(SEK 000s)	Jun. 30 2026	Jun. 30 2025	Dec. 31 2025
Assets			
Non Current assets	171,970	63,382	117,487
Deferred tax assets	0	0	0
Current assets	53,018	53,437	44,867
Cash and cash equivalents	130,043	154,071	139,889
Total assets	**355,031**	**270,890**	**302,243**
Equity and liabilities			
Restricted equity	18,970	17,795	18,021
Unrestricted equity	283,382	233,464	242,654
Untaxed reserves	515	0	515
Liabilities			
Non Current liabilities	9,490	7,133	5,521
Current liabilities	42,674	12,498	35,532
Total equity and liabilities	**355,031**	**270,890**	**302,243**

Statement of Changes in Equity

(SEK 000s)	Jun. 30 2026	Jun. 30 2025	Dec. 31 2025
Opening balance	260,675	236,740	236,740
Profit for the period	13,844	14,519	8,087
Proceeds from new share issue, net*	27,833	0	15,848
Amount at end of period	**302,352**	**251,259**	**260,675**
Attributable to shareholders in Genovis AB	302,352	251,259	260,675

**Total costs for the new share issue amounted to SEK 218 thousand.*

Condensed Statement of Cash Flows

	Apr-Jun		Jan-Jun		full year
(SEK 000s)	2026	2025	2026	2025	2025
Operating profit for the period	**9,791**	**8,015**	**16,390**	**14,700**	**24,864**
Adjustment for items not affecting cash flow	1,144	915	2,270	1,842	4,050
Changes in working capital	-2,978	-11,226	-4,666	-19,463	-4,973
Net financial items	653	780	1,402	1,633	2,435
Cash flow from operating activities	**8,610**	**-1,516**	**15,396**	**-1,288**	**26,376**
Investing activities	-55,995	-9,378	-56,752	-9,898	-66,212
Cash flow after investing activities	**-47,385**	**-10,894**	**-41,356**	**-11,186**	**-39,836**
Financing activities	31,510	7,133	31,510	7,133	21,601
Cash flow for the period	**-15,875**	**-3,761**	**-9,846**	**-4,053**	**-18,235**
Cash and cash equivalents at start of period	145,918	157,832	139,889	158,124	158,124
Cash and cash equivalents at end of period	**130,043**	**154,071**	**130,043**	**154,071**	**139,889**

Statement by the Board of Directors and Chief Executive Officer

The Board of Directors and the Chief Executive Officer certify that this interim report provides a true and fair overview of the development of the Parent Company's and the Group's business activities, financial position and results of operations as well as the significant risks and uncertainties to which the Parent Company and the companies included in the Group are exposed.

Kävlinge, July 23, 2026
Genovis AB (publ.)

On behalf of the Board of Directors Fredrik Olsson
Chief Executive Officer

For more information

Additional information about the Company is available on its website: www.genovis.com
For questions about this report, please contact: Fredrik Olsson, CEO, and President,
Tel.: +46 (0)702-276 46 56. E: fredrik.olsson@genovis.com

This information is information that Genovis AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on July 23, 2026.

This is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.